Genetic Links Between the Acute-Phase Response and Arthritis Development in Rats

Peter Olofsson,1 Niklas Nordquist,2 Carina Vingsbo-Lundberg,1 Anders Larsson,3 Cecilia Falkenberg,1 Ulf Pettersson,2 Bo Åkerström,1 and Rikard Holmdahl 1

Objective. The acute-phase inflammatory response is closely correlated with the development of rheumatoid arthritis, but the pathophysiologic role of its specific components is largely unknown. We investigated the genetic control of the acute-phase protein response in pristane-induced arthritis (PIA), which is a chronic erosive arthritis model in rats.

Methods. Plasma levels of the acute-phase proteins interleukin-6 (IL-6), α1-acid glycoprotein (orosomucoid), fibrinogen, and α2-inhibitor3 were quantified in 3 strains of rats during the development and progression of disease: DA and LEW.1F, which are susceptible to arthritis, and E3, which is resistant. Genetic linkage analysis was performed on an F2 intercross between E3 and DA to determine the genetic control of the acute-phase response in arthritis. Elevated levels of α1-acid glycoprotein were associated with acute inflammation, whereas levels of IL-6 were increased during the entire course of the disease.

Results. Using these acute-phase markers as quantitative traits in linkage analysis revealed a colocalization of loci controlling the acute-phase response and regions previously shown to control the development of arthritis in chromosomes 10, 12, and 14. In addition, 2 loci that were not associated with arthritis were found to regulate serum levels of the acute-phase protein Apr1 (acute-phase response 1) at the telomeric end of chromosome 12 and Apr2 on chromosome 5.

Conclusion. The PIA model in rats is a useful tool for understanding some of the pathways leading to chronic erosive arthritis. The analysis of acute-phase proteins in PIA and its application as quantitative traits for studying the genetics of arthritis will promote the understanding of the genetic regulation of the acute-phase response.

Rheumatoid arthritis (RA) primarily affects the peripheral joints, where a chronic inflammatory synovitis often results in cartilage destruction, bone erosion, and ultimately, joint deformity and loss of function. The pathogenesis of RA is poorly understood, and the diagnosis is based on clinical descriptions rather than an understanding of the disease mechanisms (1). Diagnosis and prediction of disease progression in RA are of great importance, since early treatment may ameliorate the later development of severe erosions and joint immobilization. Several factors have been suggested to predict a more aggressive disease course. One such factor is the DR4 locus in the major histocompatibility complex (MHC) (2,3); others are rheumatoid factors, which are elevated before the onset of arthritis (4), antibodies to citrulline-composed epitopes (5), and various acute-phase proteins (6,7).

Acute-phase proteins such as α1-acid glycoprotein (orosomucoid), fibrinogen, and α2-inhibitor3 are characterized by altered plasma levels as an outcome of inflammation (8,9). In arthritis patients, the serum concentration of acute-phase proteins strongly correlates not only with disease parameters such as joint swelling, but also with serum concentrations of interleukin-6 (IL-6) (10). IL-6 has been suggested to play a role in the pathogenesis of arthritis, as demonstrated by experiments with IL-6–deficient mice (11). One of the best
markers of inflammatory activity in RA is the acute-phase protein α1-acid glycoprotein (12,13). Determination of the glycosylation subforms of α1-acid glycoprotein may discriminate between more severe forms of disease (14,15). The role of these different acute-phase proteins in the arthritic process is largely unknown. It is therefore important to study animal models in which mechanistic studies and complex interactions in vivo can be addressed and tested.

Various rat models of arthritis are available which more or less mimic RA in humans. These models include both cartilage protein–induced arthritis, such as collagen-induced arthritis (CIA) (16), adjuvant-induced arthritis, such as oil-induced arthritis (17), and pristane-induced arthritis (PIA) (18). We chose PIA as the model for analyzing the acute-phase response in arthritis because it best fulfills the criteria used to diagnose RA (19).

In the present study, 3 strains of rats were examined: the E3 strain, which is resistant to PIA, and the DA and LEW.1F strains, which are highly susceptible to PIA (18). To investigate the potential role of acute-phase proteins in disease mechanisms of the PIA model, we analyzed plasma levels of α1-acid glycoprotein, fibrinogen, α1-inhibitor3, and IL-6, which are known to reflect the level of inflammation in arthritis (8). These proteins were measured at 16 different times, from day 0 to day 150 after pristane injection.

Based on the findings of plasma analyses, we investigated the genetic control of the acute-phase protein response in comparison with the genetic control of arthritis in an E3 × DA crossbred strain of rats. The results showed that the levels of each acute-phase protein are associated with a specific set of loci. Interestingly, most of these loci have previously been found to control various phases of arthritis.

MATERIALS AND METHODS

Animals. Pathogen-free rats of the E3, DA, and LEW.1F strain (originating from Zentralinstitut für Versuchstierzucht, Hannover, Germany) were kept in animal facilities in a climate-controlled environment with 12-hour light/dark cycles. Rats were housed in polystyrene cages containing wood shavings and were fed standard rodent chow and water ad libitum. The rats were found to be free of common pathogens, including Sendai virus, Hantaan virus, coronavirus, reovirus, cytomegalovirus, and Mycoplasma pulmonis.

Breeding to produce (E3 × DA)F2 offspring was performed in the same pathogen-free animal facility. Female E3 rats were intercrossed to produce (E3 × DA)F1 offspring that were further intercrossed to produce (E3 × DA)F2 rats (n = 153; 70 females and 83 males), which were used in the linkage analysis.

Induction and evaluation of arthritis. Arthritis was induced by an intradermal injection at the base of the tail with 150 μl of pristane (2,6,10,14-tetramethylpentadecane; Aldrich, Milwaukee, WI). Four groups of F2 animals were challenged with pristane and showed only small and not significant variations in the severity and onset of arthritis (data not shown). These groups were therefore combined for analysis.

The parental E3, DA, and LEW.1F rats were challenged simultaneously with pristane. Arthritis was induced in all rats at the age of 8–12 weeks. Arthritis development was monitored in all 4 limbs, using a macroscopic scoring system. For each limb, 1 point was given for each swollen or red toe, 1 point for each swollen midfoot, digit, or knuckle, and 5 points for a swollen ankle (maximum score per limb 15). The scores of the 4 limbs were added to yield a total score for each rat (maximum total score per rat 60).

The rats were examined 1–4 times a week for 150 days after pristane injection. Blood was obtained by cutting the tip of the tail. To prevent blood coagulation, 10 μl of heparin (5,000 units/ml; Lövens Läkemedel, Malmö, Sweden) was mixed with 500–1,000 μl of blood. The plasma was separated from blood cells by centrifugation and stored at −70°C until assayed. Plasma from parental strains was collected on days 0, 4, 8, 12, 16, 20, 25, 30, 35, 42, 49, 60, 80, 100, 120, and 150 after pristane injection. Serum was collected from the (E3 × DA)F2 rats on days 14, 35, 49, and 100.

Determination of plasma protein concentrations. Levels of α1-acid glycoprotein were measured with a soluble competitive radioimmunoassay (RIA) using rat α1-acid glycoprotein (Zivic-Miller Laboratories, Zelienpole, PA) and a polyclonal rabbit antibody against α1-acid glycoprotein (Agrisera, Vännäs, Sweden) (20). Concentrations of α1-inhibitor3 were measured with a solid-phase RIA (21) modified as described elsewhere (22), using polyclonal rabbit antibody against α1-inhibitor3 (Agrisera) and purified rat α1-inhibitor3 generously provided by Dr. Jan J. Enghild (Institute of Molecular and Structural Biology, University of Aarhus, Aarhus, Denmark) as standard.

Plasma concentrations of IL-6 were determined using the IL-6–dependent cell line B9 (23). The B9 cells were cultured in Dulbecco’s Glutamax medium supplemented with streptomycin, penicillin, 10% fetal calf serum, and recombinant rat IL-6 (RDI-4016; Research Diagnostics, Flanders, NJ). B9 cells washed in phosphate buffered saline (0.14M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4), cultured in media containing the plasma samples for 72 hours, and pulsed with 3H-thymidine overnight. Cells were then harvested in a Filtermate cell harvester (Packard Instruments, Meriden, CT). The incorporation of 3H-thymidine was determined in a Matrix 96 direct beta counter (Packard Instruments). The level of IL-6 in the plasma was determined by comparison with the standard curve of the recombinant rat IL-6 included in each plate. The detection limit of the assay was 2.5 pg/ml.

Plasma fibrinogen was determined by rate nephelometry on a Beckman Array protein system (Beckman Instruments, Brea, CA) utilizing chicken anti-human fibrinogen (Immunosystem, Uppsala, Sweden). A pool of normal rat plasma was used to produce a standard curve, which was then used to calculate the fibrinogen content in the samples (24).
Immunohistopathologic analyses. The ankle joints from the hind paws were obtained on day 150 after pristane injection, when the rats were killed. The paws were fixed in 4% paraformaldehyde, decalcified in EDTA, embedded in paraffin, sectioned, and stained with hematoxylin and erythrosin.

Genotyping and linkage analysis. DNA was prepared from tail biopsy tissues as previously described. Primer sequences for rat microsatellite markers defined as DxMity, DxMghy, DxRaty, and DxGoty were obtained from Research Genetics (Huntsville, AL), and for markers defined as DxWoxy from the Wellcome Institute for Human Genetics (Oxford, UK). Fluorescent-labeled primers were synthesized by Interactiva Biotechnologie (Ulm, Germany).

All markers were assayed by polymerase chain reaction (PCR) on an ABI 877 Integrated Thermal Cycler (Perkin Elmer, Emeryville, CA) according to a standard protocol, and PCR products were run on an ABI 377 DNA Sequencer (Perkin Elmer). Data were analyzed with the software packages GeneScan 3.1 and Genotyper 2.1 (Perkin Elmer) through comparison with amplified samples from parental strain rats.

To produce linkage maps covering the complete genome, all 153 $F_2$ progeny were genotyped using 323 markers. More than 95% of the rat genome was within a 10-cM distance of 1 microsatellite marker (maximum intermarker distance 28 cM). An improved linkage map based on several crosses involving E3 and DA is available at our Internet site (http://net.inflam.lu.se). Linkage analysis was performed with the MapMaker computer package (27–29). The MapMaker/QTL software used for the quantitative trait locus (QTL) analysis and chromosomal QTL maps showing the logarithm of likelihood (LOD) of the presence of a QTL controlling disease or plasma protein levels utilizes interval mapping calculations and provides determinations of the linkage inheritance pattern (dominant, additive, or recessive). For claiming significant linkage, we used a threshold of LOD $\geq 3.4$ and for suggestive linkage, we used a threshold of LOD 2.8, as described previously (30), which is based on the guidelines suggested by Lander and Kruglyak (27).

Statistical analyses other than linkage analysis were performed using Student’s unpaired $t$-test.

RESULTS

Arthritis disease course. Clinical manifestations of arthritis after pristane injections were characterized in 3 different rat strains: E3, DA, and LEW.1F (Table 1 and Figures 1 and 2). DA and LEW.1F rats displayed 100% incidence of severe and chronic arthritis, with a mean onset occurring on day 14 and day 17, respectively. E3 rats did not develop arthritis. The development of chronic arthritis led to a reduction in normal weight gain of both DA and LEW.1F rats. In both the DA and the LEW.1F rat strains, the arthritis was symmetric.

| Strain | No. of rats | Incidence of arthritis, % | Maximum clinical score, mean ± SD† | No. of affected paws, mean ± SD‡ | Cumulative score, mean ± SD§ | Arthritis onset, mean ± SD days | Incidence of tail ankylosis, % |
|--------|------------|---------------------------|-----------------------------------|-------------------------------|-----------------------------|-------------------------------|-----------------------------|
| DA     | 10         | 100                       | 31 ± 14                           | 3.7 ± 0.5                     | 370 ± 282                   | 14 ± 1                        | 75                          |
| E3     | 10         | 0                         | 0                                 | 0                             | 0                           | –                             | 0                           |
| LEW.1F | 11         | 100                       | 37 ± 13                           | 3.4 ± 0.7                     | 423 ± 174                   | 17 ± 3                        | 0                           |

* Arthritis severity was evaluated as described in Materials and Methods (maximum score per rat 60). The maximum clinical score is the value for each rat at the time of the most severe arthritis.
† Mean number of paws per rat with clinical signs of arthritis at the time of the most severe arthritis.
‡ Total of arthritis scores for all scoring done during the experiment.
§ Cumulative score.
On average, 85% of the arthritic hind joints were symmetrically affected during the period of most severe arthritis, from day 22 to day 35 after pristane injection. The DA rats showed more severe deformity of the paws and more pronounced active chronic arthritis, with a relapsing phase starting around day 60 after pristane injection, whereas the LEW.1F rats showed a more edematous type of joint swelling and a less erosive chronic phase (Figures 1 and 2). The weight of the rats was mainly affected during the disease onset period (Figure 1). Ankylosis in the tail was observed in 75% of the DA rats but in none of the E3 or LEW.1F strains (Table 1). The ankylosis in the tail correlated with severe deformity of the arthritic paws. The most severely affected DA rats also had signs of a bent back, possibly as a result of ankylosis of the vertebral column (data not shown).

Hind paw ankles were analyzed with hematoxylin and erythrosin staining on day 150 after arthritis induction to visualize the cell infiltration and joint erosions (Figure 3). The E3 rat we examined had normal joints, with no cell infiltration or degraded cartilage. Synovial inflammation and joint erosion were seen in both the DA and LEW.1F rats. However, DA rats had a more severe pannus and greater erosions of cartilage and bone.

Analysis of acute-phase proteins. To investigate whether pristane injection and the development of chronic arthritis induced an acute-phase response, we determined the levels of various acute-phase proteins in blood plasma from the E3, LEW.1F, and DA strains at different times (Figure 2).

Fibrinogen levels were increased 2-fold in all strains following pristane injection and before the onset of arthritis. The arthritis onset in the DA and LEW.1F
rats significantly prolonged the elevated fibrinogen level (P < 0.01 versus the E3 strain). In the chronic phase of the disease, the DA rats showed relapses of increased fibrinogen, possibly reflecting the relapsing arthritis in this strain. Levels of α1-acid glycoprotein were increased ~10-fold in the DA and LEW.1F rats, whereas the E3 strain only showed a minor increase (P < 0.05). The increase started at the onset of arthritis, continued to increase until maximum arthritis severity was reached, and then returned to normal levels as the acute inflammation subsided. Around day 80, the level of α1-acid glycoprotein was slightly elevated in the DA strain (P < 0.05 versus the E3 strain).

Figure 3. Immunohistochemical analysis of paraffin sections of the hind paw ankle joints of A, DA, B, E3, and C, LEW.1F rats obtained on day 150 after pristane injection. The sections from the DA and LEW.1F rats are representative of all rats with the same clinical scores. The section from the E3 rat is totally unaffected, while the sections from the DA and LEW.1F rats clearly show active inflammation. Due to the severe erosion of bone and cartilage in both the DA and LEW.1F strains, the entire joint has been engulfed in pannus, the joint is completely destroyed, and there is ankylosis, causing severe immobilization of the joint. (Hematoxylin and erythrosin stained; original magnification × 100.)

Levels of the negative acute-phase reactant α1-inhibitor3 were reduced at arthritis onset in the arthritis-susceptible DA and LEW.1F strains, but remained constant in the arthritis-resistant E3 strain during the same time period (P < 0.05). The reduced levels in DA and LEW.1F rats remained low during the chronic phase of arthritis.

All strains had higher levels of IL-6 on day 10 after pristane injection (i.e., before arthritis onset). The arthritis-susceptible DA and LEW.1F strains had higher levels of IL-6 compared with the E3 strain (P < 0.01). The higher levels were maintained during the first period of active arthritis. During the chronic phase, the DA rats showed steadily higher levels of IL-6, whereas the LEW.1F rats showed decreasing levels, reflecting differences in the disease course.

Taken together, the results show that a strong acute-phase protein response both precedes and occurs during PIA. Interestingly, the various acute-phase proteins showed unique patterns of response during active PIA and in connection with the different types of chronic active arthritis seen in the DA and LEW.1F strains. The strain-specific acute-phase protein responses after pristane injection are most likely genetically determined, but the observed correlation with the development of arthritis could be a secondary phenomenon. To investigate the regulation of the various acute-phase proteins in PIA, we performed a genetic study to identify the specific genetic control for each of the
levels of was found also to be associated with elevated serum chromosome 12 (rats (30,32 somal regions as previously published arthritis QTLs in serum was taken from 153 (E3 the acute-phase reaction in PIA is genetically regulated, with the genetic control of arthritis. Responding acute-phase proteins, and we compared this with the genetic control of arthritis.

**Linkage analysis.** To address the question of how the acute-phase reac

Table 2. Quantitative trait loci regulating the acute-phase protein concentration in (E3 × DA)F2 intercross rats with pristane-induced arthritis

| Phenotype* | Marker | Inheritance pattern | LOD | Variance, %† | Locus | Reference‡ |
|------------|--------|---------------------|-----|--------------|-------|------------|
| α1-acid glycoprotein | | | | | | |
| d14 (M) | D9Wox17 | Recessive | 2.9 | 25 | Cia15, Ciaa3 | 32, 43 |
| d14 (M)$ | D12Rat10 | Recessive | 6.0 | 35 | Pia4, Cia12 | 30, 32 |
| d14 (M)$ | D12Mgh11 | Recessive | 6.1 | 35 | Apr1¶ | Present study |
| α1-inhibitor3 | d14 (M)¶ | D12Mgh11 | Recessive | 2.8 | 18 | Apr1¶ | Present study |
| d49 | D1Wox25 | Additive | 3.2 | 11 | Eae7 | 48 |
| d49¶ | D5Wox10 | Dominant | 3.7 | 8 | Apr2¶ | Present study |
| Interleukin-6 | | | | | | |
| d14¶ | D14Mgh3 | Recessive | 3.7 | 11 | Pia6 | 30 |
| d14 (F) | D1Mgh21 | Dominant | 3.0 | 19 | Eae6 | 48 |
| d35 (M)¶ | D12Wox14 | Recessive | 6.7 | 31 | Pia4 | 30 |
| d35 | D18Mgh1 | Recessive | 2.8 | 12 | Cia17 | 43 |
| d49¶ | D10Mgh9 | Additive | 3.9 | 12 | Oia3, Cia5 | 34, 35 |

* Phenotypes are described in Materials and Methods. Letters in parentheses indicate that the linkage was found in only one sex (M = male; F = female).
† Extent to which the observed phenotype can be accounted for by this locus.
‡ Significant linkages found in published studies of rat arthritis models.
§ Significant linkage (logarithm of odds [LOD] score >3.4).
¶ New locus representing the acute-phase response. Two new loci were identified: Apr1 and Apr2.

We also found 2 significant loci that were associated with an acute-phase protein response which have not previously been observed to be associated with PIA. Linkage with α1-acid glycoprotein on day 14 was found on a locus near the telomeric end of chromosome 12, with an LOD score of 6.1 that was inherited in a DA recessive manner in males. This new locus was named Apr1 (representing the acute-phase response). Another previously undetected linkage was found between α1-inhibitor3 on day 49 and a locus on chromosome 5 (Apr2), which was inherited in a DA dominant manner (Figure 4). In addition, we listed in Table 2 the identified suggestive loci, several of which are colocalized with previously identified arthritis loci.

**DISCUSSION**

The present genetic analysis of rat strains with variable susceptibility to chronic erosive arthritis induced by pristane shows a close correlation between the acute-phase response and some, but not all, genetic regions that control erosive arthritis. We were able to follow the acute-phase response through different phases of the disease: the initial response to the pristane injection, the process leading to the onset of arthritis, the outbreak of severe arthritis, and the development of chronic arthritis. This was achieved through a comparison of 3 different rat strains.
The DA strain had the most severe disease, with early onset and a chronic relapsing arthritis with severe erosions of the joints. The DA strain also experienced ankylosis of the tail. The presence of more deformities and erosions in the paws of this strain was probably a result of the intense chronic/relapsing phase of arthritis. The LEW.1F strain also developed a severe erosive arthritis with a subsequent chronic arthritis but with less severe erosions of the joints (Figures 1 and 2). The LEW.1F strain had more pronounced edematous joints during the first acute phase, but less severe erosions and deformities and no tail ankylosis. The E3 strain was resistant to PIA but had a minor acute-phase response after the pristane injection; this was identified as minor alterations in the plasma levels of acute-phase proteins (Figure 2).

The mechanism of PIA that leads to differences in susceptibility and development of arthritis is unclear, as it is in other arthritis models and in RA in humans. However, it is known that PIA is strictly dependent on activation of α/β T cells, since depletion of T cells prevents PIA and has therapeutic effects on the chronic phase if α/β T cells are depleted after the onset of disease (18). Interestingly, PIA is MHC associated and the association is not primarily with susceptibility, but rather, with chronic severity (18), as has been suggested for the association of MHC in RA (3). However, there is no clear evidence in PIA for any immune response to cartilage proteins (Olofsson P, et al; unpublished observations). This is in contrast to RA, where antibodies specific for various cartilage proteins, such as type II collagen, are detectable in a substantial proportion of patients (36) and is correlated with HLA–DR alleles (37).

Thus, in PIA, we are searching for non–antigen-specific factors that may play a role in the autoimmune response. One such process is the acute-phase protein response, which is also closely associated with RA (9) and seems to be evoked in animal models of arthritis (8). There is, however, very limited knowledge on the precise role of the various acute-phase proteins in inflammation and their relevance for arthritis.

The acute-phase response is the immediate reaction to inflammation. Three key regulators of the acute-phase response are IL-6, IL-1, and tumor necrosis factor (TNF). Hepatocytes in the liver produce the acute-phase proteins. These proteins can be divided into 2 types; type 1 acute-phase proteins (α1-acid glycoprotein, serum amyloid A, complement component C3, and haptoglobin) are regulated by IL-1 and TNF, and type 2 acute-phase proteins (fibrinogen, α1-antitrypsin, and α2-macroglobulin) are regulated by IL-6 (6). The glucocorticoids, which are regulated through cytokine stimulation via the central nervous system, represent another stimulatory factor of the acute-phase response. The glucocorticoids are strong up-regulators of α1-acid glycoprotein (6,38).

Analysis of acute-phase proteins and cytokines in the blood of rats is somewhat hampered by the lack of specific antibodies and assays. For example, we analyzed TNFα, but the levels in the circulation were below the detection limit of the assay (data not shown). We also analyzed plasma concentrations of glucocorticoids, but the influence of daily rhythms and stress was of such importance that the data could not be interpreted (data not shown). Attempts to analyze α2-macroglobulin and α1-antitrypsin in plasma using sodium dodecyl sulfate–polyacrylamide gel electrophoresis failed because of a lack of rat-specific antibodies (data not shown). Since a
successful linkage analysis of quantitative traits largely depends on assays in which the phenotypes can be analyzed in a high throughput manner, we chose to focus on the acute-phase proteins fibrinogen, $\alpha_1$-acid glycoprotein, and $\alpha_1$-inhibitor3 and the cytokine IL-6.

Fibrinogen is an acute-phase protein that is increased in plasma immediately after pristane injection. All rat strains we examined (DA, E3, and LEW.1F) showed increased levels of fibrinogen regardless of their susceptibility to PIA. This feature argues that the difference in arthritis susceptibility in these rat strains is independent of the systemic reaction to pristane that leads directly to increased levels of fibrinogen. The elevated fibrinogen concentrations seen in the DA rat during the second phase of active inflammation that starts around day 80 after pristane injection supports this hypothesis.

The $\alpha_1$-acid glycoprotein level showed a strong correlation with arthritis in the susceptible rat strains (DA and LEW.1F) and is therefore very useful as a plasma marker of active inflammation. During the period of most severe arthritis, $\alpha_1$-acid glycoprotein plasma levels were significantly different between the healthy E3 rats and the arthritis-susceptible DA and LEW.1F rats ($P < 0.05$). The function and mechanism of $\alpha_1$-acid glycoprotein regulation remain unclear. It has been suggested that the protein plays an immunoregulatory role, owing to its ability to interfere with leukocytes through binding to selectins (39). Thus, the increased levels of $\alpha_1$-acid glycoprotein may reflect a feedback mechanism that prevents the infiltration of leukocytes during inflammation.

The finding that the levels of $\alpha_1$-acid glycoprotein during the development of arthritis (day 14) were linked to the $Pia4$ locus, but not other PIA loci, indicates a direct role of $\alpha_1$-acid glycoprotein in the pathogenic pathway leading to arthritis that is related to $Pia4$. The observation that the strongest linkage to the $\alpha_1$-acid glycoprotein levels was observed earlier (day 14) than the linkage to arthritis severity (day 35) suggests that it is involved in a primary mechanism in the pathogenic pathway. The observation that the $\alpha_1$-acid glycoprotein levels showed a stronger correlation in male rats but the arthritis linkage to $Pia4$ was not sex specific could argue for the possibility that different genes control these traits. However, in this context it is worth noting that pregnancy, through the effects of estrogens, influences both the levels and the glycosylation of $\alpha_1$-acid glycoprotein (15). It is therefore likely that the $\alpha_1$-acid glycoprotein response has a sex-specific regulation.

Interestingly, the strong linkage to $Apr1$, which is located on chromosome 12 although it is distinct from $Pia4$, again shows that genes that are not related to arthritis control the levels of $\alpha_1$-acid glycoprotein. In rat chromosome 12, the 2 QTLs $Pia4$ and $Cia12$ (30,32) coincide. $Apr1$ seems to be regulated by genes that are distinct from $Pia4$ and $Cia12$, as shown in Figure 4. The $Apr2$ region (separate from the $Pia4$ locus) is also involved in antibody production in PIA (Olofsson P, et al: unpublished observations), which further strengthens the position of this QTL as being separate from the QTL region covering $Pia4$ and $Cia12$.

The negative acute-phase protein $\alpha_1$-inhibitor3 is a homolog of $\alpha_2$-macroglobulin that has been found only in the plasma of rodents (40). It has been shown in both CIA and Mycobacterium-induced arthritis that the concentration of $\alpha_1$-inhibitor3 decreases during inflammation (41,42). As expected, levels of $\alpha_1$-inhibitor3 were clearly decreased in the susceptible DA and LEW.1F strains compared with the E3 strain ($P < 0.005$), showing large between-strain differences during the acute, severe phase of the arthritis. However, genetic analysis showed that the levels of $\alpha_1$-inhibitor3 were not associated with arthritis loci. Instead, a new locus was found on chromosome 5 ($Apr2$), and a suggestive linkage was also found with $Apr1$. The $Apr2$ locus on chromosome 5 is located near a previously published QTL ($Ciaa5$) that showed suggestive linkage to antibody titers in CIA (43). This finding might indicate that QTLs for the acute-phase response which do not coincide with QTLs previously assigned to clinical disease in arthritis models might be loci that are also involved in the antibody production pathway.

It has been suggested that IL-6 is one of the most important regulators of acute-phase proteins (13). Elevated levels of IL-6 have been detected in serum in both RA patients (10) and rodent models of arthritis (44). In the mouse CIA model, IL-6 is expressed in the joints as one of the earliest markers of inflammation (45). It has been reported that IL-6–deficient mice are either not susceptible to arthritis (46) or have a delayed onset, although with a similar incidence of CIA as in wild-type control mice (11). Blockage of the IL-6 receptor with monoclonal antibodies was shown to reduce the severity of CIA in mice (47). Thus, it is clear that IL-6 is an important factor in the first acute phase of arthritis. This was also indicated in our PIA model by the elevated IL-6 levels in the susceptible rat strains. However, our findings also showed that there was a recurrence of IL-6 production associated with the relapsing phase of arthritis, which is of critical importance for comparison with RA. Interestingly, this recurrence is genetically deter-
mined, since only the DA strain, with a more pronounced relapsing arthritis, had elevated IL-6 levels, whereas the LEW.1F strain had elevated levels only during the acute phase.

The loci controlling the IL-6 levels colocalize with arthritis loci. The Pia4 locus on chromosome 12 also controls the level of IL-6 in serum on day 35, the time point at which this locus showed the strongest association with arthritis. The levels of IL-6 at an earlier time point (day 14) were more strongly associated with another locus, Pia6, on chromosome 14. Surprisingly, this locus was associated with chronic arthritis rather than arthritis onset. If the same gene controls these traits, IL-6 could be an initiator of this pathway.

In summary, genetic analysis revealed that serum levels of each acute-phase protein we examined (α1-acid glycoprotein, α1-antitrypsin, and IL-6) are controlled by different sets of QTLs, and that many of these coincided with QTLs for clinical phenotypes of arthritis (30,32,34,43). In addition, 2 new loci were identified (Apr1 and Apr2), suggesting that part of the acute-phase response is regulated by mechanisms that are different from those controlling the clinically observable arthritis. These results show that plasma proteins, such as the acute-phase proteins, are excellent phenotypic markers for analyzing the genetics of arthritis. Clearly, the genetic control of arthritis is influenced by sex. About half of the loci identified so far have different effects in males and females (30,43).

We believe that the PIA model in rats will be a useful tool for unraveling some of the pathways that lead to chronic erosive arthritis as seen in RA. With different rat strains, this model can be used to study the different manifestations of arthritis. By the use of blood markers, such as the acute-phase protein α1-acid glycoprotein, a better analysis of the development of arthritis can be achieved. Since these blood markers can be used to study the genetics of arthritis, they are also of great value for the isolation of polymorphic genes in the various QTLs in congenic strains and are also accessible for corresponding analysis in humans.

ACKNOWLEDGMENTS

We thank L. Lindström for taking care of the animals, Ludmila Elfineh for expertise and assistance in genotyping, and Alexandra Threschow for linguistic help.

REFERENCES

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307–10.

2. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA–DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum 1999;42:757–62.

3. Weyand CM, Goronzy JJ. HLA polymorphisms and T cells in rheumatoid arthritis. Int Rev Immunol 1999;18:37–59.

4. Aho K, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Leino A, et al. Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis 1997;56:351–6.

5. Schellekens GA, de Jong BA, van den Hoogen FH, de van Deute LB, van Venrooj WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273–81.

6. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74–80.

7. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521–8.

8. Billingham ME, Gordon AH. The role of the acute phase reaction in inflammation. Agents Actions 1976;6:195–200.

9. Schultz DR, Arnold PJ. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, α1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990;20:129–47.

10. Housiaux FA, Devogelaer JP, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784–9.

11. Sasai M, Sacki Y, Oshima S, Nishio K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6–deficient mice. Arthritis Rheum 1999;42:1635–43.

12. Poole AR, Witter J, Roberts N, Piccolo F, Brandt R, Paquin J, et al. Inflammation and cartilage metabolism in rheumatoid arthritis: studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. Arthritis Rheum 1990;33:790–9.

13. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000;1482:157–71.

14. Van Dijk W, Mackiewicz A. Interleukin-6-type cytokine-induced changes in acute phase protein glycosylation. Ann N Y Acad Sci 1995;762:319–30.

15. Havenaar EC, Axford JS, Brinkman-van der Linden EC, Alavi A, Van Ommen EC, Van het Hof B, et al. Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in α1-fucosylation of α1-acid glycoprotein. Glycoconj J 1998;15:723–9.

16. Griffiths MM, DeWitt CW. Genetic control of collagen-induced arthritis in rats: the immune response to type II collagen among susceptible and resistant strains and evidence for multiple gene control. J Immunol 1984;132:2850–6.

17. Kleinau S, Erlandsson H, Holmahl R, Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J Autoimmun 1991;4:871–80.

18. Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, Holmahl R. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol 1996;149:1675–83.

19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

20. Akesson B. Immunological analysis of α1-microglobulin in different mammalian and chicken serum: α1-microglobulin is 5.8 kilodaltons larger in primates. J Biol Chem 1985;260:4839–44.

21. Nilson B, Bjorck L, Akesson B. Detection and purification of rat and goat immunoglobulin G antibodies using protein G-based
solid-phase radioimmunoassays. J Immunol Methods 1986;91:275–81.
22. Falkenberg C, Enghild JJ, Thogersen IB, Salvesen G, Akerstrom B. Isolation and characterization of fibronectin-α1-microglobulin complex in rat plasma. Biochem J 1994;301:745–51.
23. Aarden LA, De Grooth ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by human monocyttes. Eur J Immunol 1987;17:1411–6.
24. Larsson A, Bjork J, Lundberg C. Nephelometric determination of rat fibrinogen as a marker of inflammatory response. Vet Immunol Immunopathol 1997;59:163–9.
25. Jonsson R, Tarkowski A, Klareskog L. A demineralization procedure for immunohistopathological use: EDTA treatment preserves lymphoid cell surface antigens. J Immunol Methods 1986;88:109–14.
26. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991;19:4293.
27. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241–7.
28. Lincoln SE, Daly MJ, Lander ES. Constructing genetic maps with MapMaker/EXP version 3.0: a tutorial and reference manual. 3rd ed. Cambridge (MA): Whitehead Institute; 1993. Accessed Nov. 27, 2001. URL: http://www-genome.wi.mit.edu/genome_software/other/mapmaker.html.
29. Lincoln SE, Daly MJ, Lander ES. Mapping genes controlling quantitative traits using MapMaker/QLT version 1.1: a tutorial and reference manual. 2nd ed. Cambridge (MA): Whitehead Institute; 1993. Accessed Nov. 27, 2001. URL: http://www-genome.wi.mit.edu/genome_software/other/qlt.html.
30. Vingsbo-Lundberg C, Nordquist N, Olofsson P, Sundvall M, Saxne T, Pettersson U, et al. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat Genet 1998;20:401–4.
31. Lander ES, Green P, Abrahamson J, Barlow A, Daly MJ, Lincoln SE, et al. Mapmaker: an interactive computer package for constructing primary genetic linkage maps of experimental and natural populations. Genomics 1987;1:174–81.
32. Griffiths MM, Wang J, Joe B, Dracheva S, Kawahito Y, Shepard JS, et al. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis. Arthritis Rheum 2000;43:1278–89.
33. Remmers EF, Longman RE, Du Y, O’Hare A, Cannon GW, Griffiths MM, et al. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat Genet 1996;14:82–5.
34. Lorentzen JC, Glaser A, Jacobsson L, Galli J, Fakhrai-rad H, Klareskog L, et al. Identification of rat susceptibility loci for adjuvant-oid-induced arthritis. Proc Natl Acad Sci U S A 1998;95:6383–7.
35. Gulko PS, Kawahito Y, Remmers EF, Reese VR, Wang J, Dracheva SV, et al. Identification of a new non-major histocompatibility complex genetic locus on chromosome 2 that controls disease severity in collagen-induced arthritis in rats. Arthritis Rheum 1998;41:2122–31.
36. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000;27:575–81.
37. Kњubek AD, Stockman A, Brand CA, Tait BD, Mackay IR, Murden KD, et al. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 1999;42:2569–76.
38. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81–8.
39. Brinkman-van der Linden EC, de Haan PF, Havenaar EC, van Dijk W. Inflammation-induced expression of sialyl Lewisx is not restricted to α1-acid glycoprotein but also occurs to a lesser extent on α1-antichymotrypsin and haptoglobin. Glycoconj J 1998;15:177–82.
40. Ennard F, Gutman N, el Moujahed A, Gauthier F. Rat plasma α1-inhibitor, a member of the α-macroglobulin family. FEBS Lett 1985;182:125–9.
41. Lomberg-Holm K, Reed DL, Roberts RC, Hebert RR, Hillman MC, Kutney RM. Three high molecular weight protease inhibitors of rat plasma: isolation, characterization, and acute phase changes. J Biol Chem 1987;262:438–45.
42. Falkenberg C, Blom A, Fries E, Ekstrom G, Sarnstrand B, Salier JP, et al. Alpha-1-microglobulin and bikunin in rats with collagen II-induced arthritis: plasma levels and liver mRNA content. Scand J Immunol 1997;46:122–8.
43. Furuya T, Salstrom JL, McCall-Vining S, Cannon GW, Joe B, Remmers EF, et al. Genetic dissection of a rat model for rheumatoid arthritis: significant gender influences on autosomal modifier loci. Hum Mol Genet 2000;9:2241–50.
44. Sugita T, Furukawa O, Ueno M, Murakami T, Takata I, Tosa T. Enhanced expression of interleukin 6 is required for the development of collagen-induced arthritis: significant gender influences on autosomal modifier loci. Hum Mol Genet 2000;9:2241–50.
45. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999;44:1109–18.
46. Aloni Z, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:1–6.
47. Takagi N, Mihara M, Moriya Y, Yoshizaki K, Kishimoto T, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:217–21.
48. Bergsteinsdottir K, Yang HT, Pettersson U, Holmdahl R. Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis. J Immunol 2000;164:1564–8.